BVXV - BiondVax Pharmaceuticals Ltd.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
5.30
-0.06 (-1.12%)
At close: 1:58PM EST
Stock chart is not supported by your current browser
Previous Close5.36
Open5.30
Bid5.27 x 800
Ask11.80 x 4000
Day's Range5.23 - 5.30
52 Week Range4.60 - 7.71
Volume2,229
Avg. Volume4,042
Market Cap34.638M
Beta (3Y Monthly)1.09
PE Ratio (TTM)N/A
EPS (TTM)-2.30
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.00
Trade prices are not sourced from all markets
  • GlobeNewswire18 days ago

    Analysis: Positioning to Benefit within Real Goods Solar, Natural Resource Partners LP, Spark Therapeutics, Social Reality, Rapid7, and BiondVax Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • BiondVax CEO to Present at 'World Vaccine Congress 2018 San Diego' About BiondVax's Phase 3 Universal Flu Vaccine Candidate
    PR Newswire20 days ago

    BiondVax CEO to Present at 'World Vaccine Congress 2018 San Diego' About BiondVax's Phase 3 Universal Flu Vaccine Candidate

    JERUSALEM, Nov. 26, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), developer of the M-001 universal influenza vaccine candidate, reported today it will present this week at the World Vaccine & Immunotherapy Congress West Coast 2018 in San Diego. Dr. Ron Babecoff, BiondVax's Founder and CEO, will participate in a panel discussion and provide an overview of the Company's achievements and plans, including the ongoing pivotal, clinical efficacy, Phase 3 trial. Panel: How will we integrate knowledge gained from the UIVI and other research into the development of a Universal Influenza Vaccine?

  • Zacks Small Cap Research26 days ago

    BVXV: Enrollment of First Season Cohort Complete in Phase 3 Trial of Universal Influenza Vaccine…

    BiondVax Pharmaceuticals,Ltd. (BVXV) is a biopharmaceutical company developing a universal influenza vaccine (M-001) designed to protect individuals from all strains of influenza. The company’s strategy for commercializing M-001 involves testing it in a pivotal Phase 3 program as a standalone influenza vaccine to assess its clinical efficacy. The first Phase 3 trial is being conducted in Europe following feedback about the trial design and approval to initiate it from the European Medicines Agency (EMA).

  • BiondVax Issues Clarification Regarding Third Quarter 2018 Financial Results
    PR Newswire27 days ago

    BiondVax Issues Clarification Regarding Third Quarter 2018 Financial Results

    JERUSALEM , Nov. 19, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu ...

  • BiondVax Announces Third Quarter 2018 Financial Results
    PR Newswirelast month

    BiondVax Announces Third Quarter 2018 Financial Results

    JERUSALEM , Nov. 13, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu ...

  • BiondVax's Universal Flu Vaccine Phase 3 Clinical Trial Completes First Season's Enrollment of 4,098 Participants
    PR Newswire2 months ago

    BiondVax's Universal Flu Vaccine Phase 3 Clinical Trial Completes First Season's Enrollment of 4,098 Participants

    The 4,098 participants enrolled in this year's cohort will be monitored for two flu seasons. A second cohort of approximately 6,000 participants will be enrolled prior to the 2019/2020 flu season. Safety, as well as laboratory confirmed influenza incidence will be assessed, with results expected in the second half of 2020.

  • BiondVax Receives €8M From the European Investment Bank (EIB) in Support of Manufacturing Facility and Ongoing Phase 3 Clinical Trial
    PR Newswire2 months ago

    BiondVax Receives €8M From the European Investment Bank (EIB) in Support of Manufacturing Facility and Ongoing Phase 3 Clinical Trial

    JERUSALEM, Oct. 22, 2018 /PRNewswire/ --  BiondVax Pharmaceuticals Ltd. (BVXV), developer of M‑001, a clinical phase 3 Universal Influenza Vaccine candidate, announced today the receipt of an €8 million disbursement from the European Investment Bank (EIB). The first two tranches totaling €12 million were received by BiondVax earlier this year.

  • GlobeNewswire2 months ago

    Report: Exploring Fundamental Drivers Behind CURO Group, BiondVax Pharmaceuticals, AMAG Pharmaceuticals, AcelRx Pharmaceuticals, Ballard Power, and Rhythm Pharmaceuticals — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Zacks Small Cap Research3 months ago

    BVXV: Phase 3 Trial of M-001 Underway…

    BiondVax Pharmaceuticals,Ltd. (BVXV) is a biopharmaceutical company developing a universal influenza vaccine (M-001) designed to protect individuals from all strains of influenza. The company’s strategy for commercializing M-001 involves testing it in a pivotal Phase 3 program as a standalone influenza vaccine to assess its clinical efficacy. The first Phase 3 trial will be conducted in Europe and the company has received feedback about the trial design and approval to conduct it from the European Medicines Agency (EMA).

  • BiondVax to Present at Influenza 2018 Oxford Conference
    PR Newswire3 months ago

    BiondVax to Present at Influenza 2018 Oxford Conference

    JERUSALEM, Sept. 4, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), developer of the M-001 universal influenza vaccine candidate, reported today it will present at the Influenza 2018 Oxford conference at the University of Oxford. Joshua Phillipson, BiondVax's Business Development Manager, will provide an overview of the Company's clinical development achievements and plans, including the recently launched pivotal, clinical efficacy, Phase 3 trial.

  • BiondVax Announces Second Quarter 2018 Financial Results
    PR Newswire4 months ago

    BiondVax Announces Second Quarter 2018 Financial Results

    JERUSALEM , Aug. 22, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu ...

  • BiondVax Moves to New Universal Flu Vaccine Manufacturing Facility
    PR Newswire4 months ago

    BiondVax Moves to New Universal Flu Vaccine Manufacturing Facility

    JERUSALEM, Aug. 20, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), developer of the M-001 universal influenza vaccine candidate, reported today the company's relocation to a newly constructed mid-size commercial scale manufacturing facility in Jerusalem, Israel. Dr. Shimon Hassin, BiondVax's COO, commented, "BiondVax's new facility is custom-built for GMP manufacturing of our innovative flu vaccine candidate, which can be produced year-round and is designed to provide broad protection against influenza.

  • BiondVax Receives Second €6M Tranche Disbursement From the European Investment Bank (EIB)
    PR Newswire4 months ago

    BiondVax Receives Second €6M Tranche Disbursement From the European Investment Bank (EIB)

    NESS ZIONA, Israel, Aug. 14, 2018  /PRNewswire/ --- BiondVax Pharmaceuticals Ltd. (BVXV), developer of M‑001, a clinical phase 3 Universal Influenza Vaccine candidate, announced today the receipt of a €6 million disbursement from the European Investment Bank (EIB). The first tranche of €6 million was received by BiondVax in June 2018[2]. Funds will be advanced in three tranches.

  • First Participant Enrolled in BiondVax's Universal Flu Vaccine Pivotal Phase 3 Clinical Trial
    PR Newswire4 months ago

    First Participant Enrolled in BiondVax's Universal Flu Vaccine Pivotal Phase 3 Clinical Trial

    The primary endpoints of the trial are to demonstrate protection from influenza and safety of M-001. A secondary endpoint will assess reduction in flu illness severity among those receiving M-001 versus placebo. In six completed clinical trials in Israel and Europe (two Phase 1/2 and four Phase 2), M-001 has been shown to be safe, well-tolerated, and immunogenic to a broad range of influenza strains.

  • Corporate Biotech Executive Mark Germain Joins BiondVax's Board of Directors
    PR Newswire6 months ago

    Corporate Biotech Executive Mark Germain Joins BiondVax's Board of Directors

    NESS ZIONA, Israel, June 28, 2018 /PRNewswire/ --  BiondVax Pharmaceuticals Ltd. (BVXV), developer of M‑001, a clinical phase Universal Influenza Vaccine candidate, announced today the appointment of Mr. Mark Germain as Vice-Chairman of its Board of Directors. Based in New York, and having served as founder, director, chairman of the board, and/or investor in over twenty biotech companies, and with experience assisting in arranging corporate partnerships, acquiring technology, entering mergers and acquisitions, and executing financings, Mr. Germain is well suited to help guide BiondVax's ongoing corporate development. Mr. Mark Germain commented, "I am pleased and excited to join the BiondVax board at this important time in the development of the company.

  • BiondVax Receives Its First €6M Tranche Disbursement From the European Investment Bank (EIB)
    PR Newswire6 months ago

    BiondVax Receives Its First €6M Tranche Disbursement From the European Investment Bank (EIB)

    NESS ZIONA, Israel, June 19, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), developer of M‑001, a clinical phase Universal Influenza Vaccine candidate, announced today the receipt of a €6 million disbursement from the European Investment Bank (EIB). Dr. Ron Babecoff, BiondVax's President and CEO, commented, "We plan to begin our first pivotal, clinical efficacy, Phase 3 trial later this year, while the construction of our mid-size commercial manufacturing facility is well underway. "We are grateful for the excellent ongoing collaboration and relationship with the EIB towards the development of our universal flu vaccine," continued Babecoff.

  • Zacks Small Cap Research7 months ago

    BVXV: Increased Media Coverage for M-001 Ahead of Phase 3 Clinical Trial

    BiondVax Pharmaceuticals,Ltd. (BVXV) is a biopharmaceutical company developing a universal influenza vaccine (M-001) designed to protect individuals from all strains of influenza. The company’s strategy for commercializing M-001 involves testing it in a pivotal Phase 3 program as a standalone influenza vaccine to assess its clinical efficacy. The first Phase 3 trial will be conducted in Europe and the company has received feedback about the trial design and approval to initiate it from the European Medicines Agency (EMA).

  • BiondVax Announces First Quarter 2018 Financial Results
    PR Newswire7 months ago

    BiondVax Announces First Quarter 2018 Financial Results

    NESS ZIONA, Israel , May 29, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu ...

  • Zacks Small Cap Research7 months ago

    BVXV: Set to Initiate Phase 3 Clinical Trial of Universal Influenza Vaccine Candidate in 2H18

    BiondVax Pharmaceuticals,Ltd. (BVXV) is a biopharmaceutical company developing a universal influenza vaccine (M-001) designed to protect individuals from all strains of influenza. The company’s strategy for commercializing M-001 involves testing it in a pivotal Phase 3 program as a standalone influenza vaccine to assess its clinical efficacy. The first Phase 3 trial will be conducted in Europe and the company has received feedback about the trial design and approval to initiate it from the European Medicines Agency (EMA).

  • BiondVax Announces Fourth Quarter and Full Year 2017 Financial Results and Update
    PR Newswire8 months ago

    BiondVax Announces Fourth Quarter and Full Year 2017 Financial Results and Update

    NESS ZIONA, Israel , April 30, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal ...

  • ACCESSWIRE8 months ago

    Blog Exposure - BiondVax Pharma Initiated NIH-Sponsored Phase-2 Clinical Trial of M-001 in the US

    Stock Monitor: Dare Bioscience Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 13, 2018 / Active-Investors.com has just released a free research report on BiondVax Pharma Ltd (NASDAQ: BVXV ) (''BiondVax''). ...

  • BiondVax to Present at Universal Influenza Vaccines Conference
    PR Newswire8 months ago

    BiondVax to Present at Universal Influenza Vaccines Conference

    NESS ZIONA, Israel , April 12, 2018 /PRNewswire/ --  BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the universal flu vaccine candidate M-001, reported today it will present at the Universal ...

  • PR Newswire8 months ago

    BiondVax Begins NIH-Sponsored Phase 2 Clinical Trial of Its Universal Flu Vaccine in the United States

    NESS ZIONA, Israel , April 11, 2018 /PRNewswire/ --   BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) reported today the first participant enrollment in the United States in a Phase 2 clinical trial of the ...